Executive Summary
Blueprint Protocol: AI Verdict
Blueprint's foundation — exercise, sleep, caloric restriction, omega-3s, and a plant-heavy diet — is among the most evidence-backed lifestyle stacks any individual could follow. The supplement layer is uneven: rapamycin and metformin are compelling; collagen and plasma exchange are not. What distinguishes Blueprint isn't the interventions but the system: the measurement, the iteration, and the published data.
Supplements & Compounds
15 Interventions
Rapamycin inhibits mTOR, a master regulator of cellular growth and aging. It is the most reproducible longevity intervention in animal models — extending lifespan in every major model organism tested, including mice given rapamycin starting at middle age. Human evidence comes primarily from safety and organ transplant data; dedicated longevity RCTs in healthy humans are still emerging from the PEARL trial and similar efforts.
Key Finding
14–16% lifespan extension in mice when started at 600 days (~60 in human years), with consistent replication across independent labs and both sexes (Harrison et al., 2009).
Metformin is the world's most prescribed diabetes drug and one of the most studied molecules in longevity science. Epidemiological data shows type 2 diabetic patients on metformin outlive non-diabetic patients not on metformin — a remarkable observation that prompted the TAME trial, the first RCT explicitly designed to test a drug against aging in healthy humans. Its mechanisms include AMPK activation, mTOR suppression, and reduced systemic inflammation.
Key Finding
Diabetic patients on metformin showed significantly lower all-cause mortality compared to non-diabetic controls — a signal strong enough to justify the $75M TAME trial (Bannister et al., 2014).
NAD+ declines with age and plays a central role in cellular energy metabolism, DNA repair, and sirtuin activation. NMN and NR both effectively raise NAD+ levels in humans — this is well-established. What is less clear is whether raising NAD+ translates to meaningful longevity or health outcomes in humans. Animal studies are impressive; human trials show some benefits (insulin sensitivity, muscle function) but longevity data does not yet exist. The mechanistic story is compelling; the clinical proof is still being written.
Key Finding
NMN supplementation (250–500mg/day) raised whole-blood NAD+ levels by up to 38% in healthy adults over 12 weeks, with improvements in physical performance in older subjects (Yoshino et al., 2021).
Low-dose lithium (distinct from psychiatric doses) has attracted longevity interest from epidemiological studies showing regions with higher natural lithium in drinking water have lower rates of dementia and longer lifespan. Animal models show lifespan extension. However, well-controlled human RCTs specifically for longevity in healthy adults are lacking, and dose-response data at supplemental doses is thin. The signal is interesting but not settled.
Key Finding
Counties with higher lithium in groundwater showed a 17% lower rate of Alzheimer's diagnoses in a large Texas cohort study — a correlation that holds across multiple regional datasets.
Ashwagandha (Withania somnifera) has well-replicated evidence for reducing cortisol and perceived stress in adults. Multiple small-to-medium RCTs show significant reductions in serum cortisol (14–30%), improvements in sleep quality, and modest effects on testosterone in men. Longevity-specific mechanisms (thyroid support, anti-inflammatory, antioxidant) are plausible but not directly demonstrated in humans for lifespan extension.
Key Finding
KSM-66 at 300–600mg/day reduced cortisol by an average of 27.9% vs. placebo over 60 days in a double-blind RCT (Chandrasekhar et al., 2012).
Cocoa flavanols have been studied extensively for cardiovascular benefits — improved endothelial function, reduced blood pressure, and increased nitric oxide bioavailability. The COSMOS-Cocoa trial (2022) showed a 27% reduction in cardiovascular death with daily cocoa flavanol supplementation — the most significant human trial to date. Evidence for longevity-specific benefits beyond cardiovascular is limited but the cardiovascular endpoint itself is a major longevity driver.
Key Finding
COSMOS-Cocoa: 500mg/day cocoa flavanols over 3.6 years reduced cardiovascular death by 27% (HR 0.73, 95% CI) in a randomized trial of 21,442 adults (Sesso et al., 2022).
Creatine is the most researched supplement in sports science with over 500 published studies. In the context of longevity, creatine's relevance stems from its strong evidence for preserving muscle mass and strength with age — sarcopenia being one of the most significant drivers of disability and mortality in older adults. Evidence for cognitive benefits (particularly in older and vegetarian populations) is also accumulating.
Key Finding
Meta-analysis of 22 RCTs: Creatine supplementation combined with resistance training increased lean mass by 1.37kg more than exercise alone in older adults (Lanhers et al., 2017).
Omega-3 fatty acids — particularly EPA and DHA — have among the strongest evidence bases of any supplement for cardiovascular, inflammatory, and cognitive outcomes. Large RCTs including VITAL and REDUCE-IT demonstrate significant reductions in major cardiovascular events. Omega-3 index (the ratio of EPA+DHA in red blood cell membranes) is increasingly used as a biomarker for longevity risk. Blueprint targets a high omega-3 index via ~4g/day EPA+DHA.
Key Finding
REDUCE-IT trial: 4g/day icosapentaenoic acid reduced major adverse cardiovascular events by 25% vs. placebo in adults with elevated triglycerides (Bhatt et al., 2019).
Vitamin D deficiency is prevalent and associated with higher all-cause mortality, cancer risk, cardiovascular disease, and immune dysfunction. The VITAL trial — a large RCT of 25,871 adults — found vitamin D3 supplementation reduced cancer mortality by 25% and cut advanced cancer incidence by 17%. Blueprint's use of higher-dose D3 (targeting serum 25-OHD above 60 ng/mL) reflects growing evidence that optimal levels are higher than historically recommended.
Key Finding
VITAL trial: 2000 IU/day vitamin D3 reduced cancer mortality by 25% (RR 0.75, 95% CI 0.58–0.99) over 5.3 years in 25,871 adults (Manson et al., 2019).
Aged garlic extract (AGE) has consistent evidence for modest blood pressure reduction, lipid modification, and anti-platelet effects. Multiple small RCTs show reductions in systolic BP of 7–16 mmHg. Anti-inflammatory effects (reduced CRP, IL-6) have been demonstrated. The cardiovascular safety profile is excellent, and garlic's inclusion in Bryan Johnson's stack is supported by a real but modest evidence base for cardiovascular protection.
Key Finding
Meta-analysis of 12 RCTs found aged garlic extract reduced systolic blood pressure by 8.4 mmHg and diastolic by 5.5 mmHg vs. placebo (Ried et al., 2016).
Glucosamine's longevity interest extends beyond its traditional joint-health use. Epidemiological studies (UK Biobank, NHANES) show glucosamine users have 15–22% lower all-cause mortality — an unexpectedly strong signal attributed to glucosamine's mTOR-inhibiting and anti-inflammatory properties. A proposed mechanism is glycolysis inhibition mimicking a low-carbohydrate metabolic state. RCT evidence for longevity endpoints doesn't yet exist; the epidemiological signal is notable.
Key Finding
UK Biobank analysis (n=495,065): Regular glucosamine use associated with 15% lower all-cause mortality and 22% lower cardiovascular mortality after full covariate adjustment (Li et al., 2020).
Lycopene — the carotenoid that gives tomatoes their red color — has strong epidemiological associations with reduced prostate cancer risk, cardiovascular protection, and reduced oxidative stress. Meta-analyses show significant inverse associations between lycopene intake and prostate cancer incidence. Its antioxidant potency (approximately twice that of beta-carotene) and lipid peroxidation reduction are mechanistically relevant to aging. Supplemental RCTs are smaller and less definitive than dietary studies.
Key Finding
Meta-analysis of 26 studies: Highest vs. lowest lycopene intake associated with 12% reduction in prostate cancer risk and 17% reduction in cardiovascular disease mortality (Rowles et al., 2017).
Curcumin has one of the broadest mechanistic profiles of any supplement — anti-inflammatory, antioxidant, neuroprotective, and anti-cancer pathways have all been documented. The challenge is bioavailability: standard curcumin is poorly absorbed. Bioavailability-enhanced forms (with piperine or phospholipid complexes) show meaningful reductions in inflammatory markers (CRP, IL-6, TNF-α) in humans. Long-term longevity endpoints in RCTs are lacking, but the anti-inflammatory evidence is credible.
Key Finding
Meta-analysis of 8 RCTs found curcumin supplementation reduced CRP by 6.44 mg/L and IL-6 by 1.23 pg/mL vs. placebo in adults with chronic inflammatory conditions (Sahebkar et al., 2016).
Zinc is an essential cofactor in over 300 enzymatic reactions and plays critical roles in immune function, DNA repair, and antioxidant defense. Zinc status declines with age, and deficiency is associated with increased inflammation and immune senescence. Supplementation in older adults with sub-optimal zinc status shows improvements in immune markers. Evidence for longevity-specific outcomes is indirect; the strongest case is for immune function preservation with age.
Key Finding
Zinc supplementation in older adults (65+) with low zinc levels reduced incidence of infections by 66% vs. placebo in a 12-month RCT — attributable to restored T-cell function (Prasad et al., 2007).
Collagen peptides are the weakest-evidence supplement in the Blueprint stack from a longevity perspective. While evidence for skin hydration, joint comfort, and tendon support exists in small industry-funded trials, collagen's systemic longevity effects are speculative. Dietary collagen is digested into amino acids and does not preferentially become collagen in your body — the proposed mechanism is indirect (via hydroxyproline stimulating endogenous production). The inclusion in Blueprint likely reflects Bryan Johnson's skin and connective tissue goals rather than a longevity primary endpoint.
Key Finding
The strongest human data is for skin elasticity — a meta-analysis of 19 RCTs found oral collagen improved skin elasticity (SMD 0.78) and hydration (SMD 0.66), primarily in women over 40. Systemic longevity effects remain undemonstrated.
Caloric restriction is one of the most reproduced longevity interventions in biology — extending lifespan in nearly every organism studied, from yeast to primates. The CALERIE trial established that 25% caloric restriction in healthy humans for 2 years significantly improved cardiovascular biomarkers, inflammatory markers, and metabolic health. Bryan Johnson's ~1,977 cal/day target (with near-perfect nutritional optimization) represents a mild-to-moderate restriction from typical intake while maintaining nutrient density.
Key Finding
CALERIE trial: 2-year 25% caloric restriction reduced cardiometabolic risk factors, lowered inflammatory biomarkers, and significantly reduced biological age measured by epigenetic clocks (Redman et al., 2018).
Extra virgin olive oil is one of the most evidence-backed dietary interventions for longevity. The PREDIMED trial — a landmark RCT of 7,447 adults — showed a Mediterranean diet supplemented with EVOO reduced cardiovascular events by 30% vs. a low-fat diet. Oleocanthal (a polyphenol in EVOO) has ibuprofen-like anti-inflammatory properties; oleic acid improves the lipid profile; and polyphenols reduce oxidative stress. Blueprint's heavy use (~15–20mL/day) targets the polyphenol dose associated with maximum benefit.
Key Finding
PREDIMED: Mediterranean diet + 4 tablespoons/day EVOO reduced cardiovascular death, MI, and stroke by 30% vs. control (HR 0.70) — a larger effect than most pharmaceutical interventions for primary prevention.
Dark chocolate's benefits largely overlap with cocoa flavanols (above). The relevant mechanism is flavanol content — which varies dramatically by processing. EVOO-grade dark chocolate (≥85% cacao, minimally processed) can provide meaningful flavanol doses. Epidemiological data shows modest dark chocolate consumption (1–6 servings/week) associated with reduced cardiovascular events. Blueprint's use is consistent with the evidence profile; portion control matters given caloric density.
Key Finding
Pooled analysis of 23 observational studies: 1–6 servings/week of dark chocolate associated with 8% lower risk of myocardial infarction and 9% lower cardiovascular mortality (Ding et al., 2006).
Nuts have remarkably consistent evidence for mortality reduction across multiple large prospective cohorts — Nurses' Health Study, Health Professionals Follow-up Study, PREDIMED. The Harvard cohort analysis of 119,000 adults showed that eating nuts ≥7 times/week was associated with 20% lower all-cause mortality. Mechanistically, nuts improve lipid profiles, reduce inflammation, provide fiber and micronutrients, and support glycemic control. This is one of the strongest diet-longevity interventions with human evidence at scale.
Key Finding
Harvard cohorts (n=119,000): Eating nuts daily associated with 20% lower total mortality, 29% lower cardiac death, and 11% lower cancer mortality vs. those who rarely ate nuts (Bao et al., 2013).
Cruciferous vegetables (broccoli, cauliflower, kale, Brussels sprouts) contain sulforaphane, indole-3-carbinol, and glucosinolates — compounds with documented anti-cancer, anti-inflammatory, and Nrf2-activating properties. Large cohort studies consistently show 10–20% lower all-cause and cancer-specific mortality in high consumers. Sulforaphane activates the body's endogenous antioxidant defense pathways more potently than direct antioxidants like vitamin C. Blueprint's emphasis on daily cruciferous consumption is strongly supported.
Key Finding
Meta-analysis of 39 prospective studies: Each additional daily serving of cruciferous vegetables associated with 8% reduction in all-cause mortality (Vieira et al., 2016).
Berries have well-replicated evidence for cognitive protection, cardiovascular benefit, and reduced inflammation. The Nurses' Health Study showed women consuming ≥2 servings of blueberries per week had cognitive aging delayed by 2.5 years. Berry polyphenols (anthocyanins, pterostilbene, resveratrol) improve insulin sensitivity, lower blood pressure, and reduce oxidative damage. The glycemic profile is favorable — high fiber content blunts blood glucose response relative to other fruits.
Key Finding
Nurses' Health Study (n=16,010): Women eating ≥2 servings of blueberries/week showed cognitive aging slowed by an equivalent of 2.5 years vs. low consumers, after adjustment for confounders (Devore et al., 2012).
A predominantly plant-based diet is associated with lower all-cause mortality, cardiovascular disease, type 2 diabetes, and several cancers across multiple large cohort studies and meta-analyses. Blueprint's near-vegan approach (with some allowances for animal protein) maximizes plant diversity, fiber, and phytonutrient intake. The health benefits appear to come from what's included (fiber, polyphenols, vitamins) as much as what's excluded (processed meat, saturated fat). Notable: protein optimization for muscle preservation requires deliberate attention on plant-only diets.
Key Finding
EPIC-Oxford cohort (n=48,188): Vegetarians had 32% lower ischemic heart disease risk vs. meat-eaters; vegans had the lowest rates of all diet groups for obesity, hypertension, and type 2 diabetes (Appleby et al., 2016).
Zone 2 cardio (low-intensity aerobic exercise sustained at ~60–70% max heart rate) is the most evidence-backed exercise modality for longevity from a metabolic and cardiovascular standpoint. It improves mitochondrial biogenesis, fat oxidation capacity, VO₂max, and cardiovascular fitness — all of which are strong independent predictors of longevity. VO₂max is arguably the single best objective predictor of all-cause mortality in longitudinal data. Blueprint targets 150+ minutes of Zone 2 per week, which aligns well with the evidence dose-response.
Key Finding
VO₂max is the single strongest predictor of all-cause mortality — moving from the bottom to the top quartile of cardiorespiratory fitness is associated with a 45% reduction in all-cause mortality (Barry et al., 2014).
Resistance training's case for longevity is compelling and distinct from cardio. Muscle mass and strength are among the strongest predictors of survival in later life — sarcopenia (age-related muscle loss) is a major driver of frailty, hospitalization, and mortality. Grip strength alone predicts all-cause mortality better than blood pressure. Strength training also improves insulin sensitivity, bone density, and metabolic health in ways that cardio alone doesn't. The dose for longevity benefit is well within reach: 2–3 sessions/week of progressive resistance training.
Key Finding
Meta-analysis of 16 prospective cohorts (n=479,856): Muscle-strengthening exercise ≥2 days/week associated with 21% lower all-cause mortality, 23% lower cardiovascular mortality, and 31% lower cancer mortality (Saeidifard et al., 2019).
Flexibility training has well-established benefits for fall prevention, joint health, and functional movement in older adults — outcomes with clear downstream longevity relevance. Direct evidence linking stretching to mortality is limited. The strongest case is indirect: maintaining functional flexibility and range of motion prevents injury, supports exercise adherence, and reduces disability risk in later decades. Blueprint includes yoga and dedicated stretching protocols; the evidence supports this as valuable maintenance work, not a primary longevity intervention.
Key Finding
Systematic review of 33 RCTs: Stretching and flexibility training significantly reduced fall risk in older adults (RR 0.84), one of the most significant predictors of morbidity and mortality post-65 (Sherrington et al., 2019).
Bryan Johnson's sleep protocol is one of the most evidence-aligned components of Blueprint. He targets a fixed 8:30pm bedtime, temperature-controlled sleeping environment (65–68°F / 18–20°C), blue light elimination 2+ hours before sleep, and uses continuous sleep tracking. Each component is supported by evidence: sleep regularity is more important than duration for mortality outcomes; cooler room temperature measurably improves slow-wave sleep; blue light suppresses melatonin onset; and sleep duration in the 7–9 hour range is associated with lowest all-cause mortality. Deviations from this protocol compound as you age.
Key Finding
Sleep regularity index (consistency of sleep timing) predicted all-cause mortality independent of duration — those with most consistent schedules had 20–48% lower mortality vs. least consistent (Phillips et al., 2017).
Red light therapy (photobiomodulation, 630–850nm wavelengths) has a plausible mechanism: photons absorbed by cytochrome c oxidase in mitochondria increase ATP production, reduce reactive oxygen species, and promote cell signaling. Evidence in wound healing, skin rejuvenation, and certain pain conditions is reasonably consistent. For systemic longevity applications — the primary Blueprint rationale — evidence is thin and mostly from small or poorly controlled trials. The mechanism is credible, the longevity evidence is not yet compelling at scale.
Key Finding
A 2018 RCT of 40 subjects found 12 weeks of photobiomodulation improved skin collagen density by 31% and reduced wrinkle depth — the most common application with measurable human endpoints. Systemic aging biomarker effects remain undemonstrated in controlled trials.
Heterochronic parabiosis experiments (surgically connecting young and old mice to share circulatory systems) showed rejuvenating effects in older animals and alarming in younger ones. This led to interest in plasma exchange and young plasma infusions. However, human evidence is essentially absent: the FDA has explicitly warned against young plasma infusions, Ambrosia LLC (a commercial young blood company) was shut down following FDA action, and published human RCTs have not demonstrated meaningful longevity or health endpoints. Bryan Johnson's participation in father-son plasma exchange was widely covered but is scientifically uncontrolled. This is the weakest evidence intervention in Blueprint.
Key Finding
A 2019 human study (Mehdipour et al.) of therapeutic plasma exchange showed improvements in some aging biomarkers — but used 5% albumin replacement, not young blood specifically, and sample sizes were small. The "young blood" hypothesis remains unproven in humans under controlled conditions.
Bryan Johnson tests over 100 biomarkers regularly — including standard blood panels, epigenetic age clocks, imaging, and functional tests. This is perhaps the most underrated component of Blueprint. The evidence that comprehensive metabolic and biomarker monitoring improves health outcomes is strong in clinical populations; for healthy aging, it enables early detection and intervention before disease manifests. The longitudinal data Johnson has accumulated is itself scientifically valuable — a rigorous N=1 experiment that no randomized trial would fund. The limitation is clear: more measurement does not automatically mean better outcomes, and false positives carry costs.
Key Finding
Repeated epigenetic age testing in the CALERIE trial showed measurable biological age deceleration in the caloric restriction group — evidence that objective aging biomarkers can track intervention effects over years, enabling real-time protocol feedback.
Bryan Johnson's oral health protocol is more rigorous than most (water flossing, tongue scraping, oil pulling, specific toothpaste). The underlying scientific case is strong: poor oral hygiene and periodontal disease are associated with systemic inflammation, cardiovascular disease, diabetes complications, and potentially Alzheimer's disease via P. gingivalis pathogen. The strength of evidence for the specific practices Johnson uses varies; flossing and brushing with fluoride toothpaste have the strongest evidence, while oil pulling has weak evidence despite widespread use.
Key Finding
Individuals with severe periodontitis have 25% higher all-cause mortality and 2x higher cardiovascular mortality vs. those with healthy gums — independent of smoking status (Holmlund et al., 2017).
Blueprint's skin care protocol centers on sun protection (SPF 50+ daily), topical tretinoin (retinoid), and other evidence-backed actives. Daily broad-spectrum UV protection has among the strongest cosmetic and dermatological evidence bases available — UV radiation is the primary extrinsic driver of skin aging and skin cancer. Tretinoin (prescription retinoid) is the gold standard for photoaging reversal with RCT evidence going back to the 1980s. While skin care isn't a primary longevity driver, UV-induced immunosuppression and melanoma risk are genuine longevity concerns.
Key Finding
Randomized Australian trial: Daily SPF 15+ sunscreen use over 4.5 years reduced melanoma incidence by 50% — demonstrating that consistent UV protection meaningfully reduces a significant longevity risk (Green et al., 2011).
Medical Disclaimer: This analysis is for informational and educational purposes only. Nothing here constitutes medical advice. Interventions like rapamycin, metformin, and blood plasma exchange are prescription or experimental treatments. Consult a qualified physician before beginning any new supplement, medication, or medical intervention. Evidence ratings reflect the scientific literature as of the analysis date and are subject to revision as new studies emerge.
Overall Protocol Assessment
Blueprint Protocol Score
Based on evidence strength of 35 scored interventions across 5 categories
14
High Evidence
14
Moderate Evidence
4
Weak Evidence
3
Mixed Evidence
Blueprint is one of the most defensible public longevity protocols ever assembled because its base layer is mainstream, high-evidence health behavior. The weak spots are the speculative edges — especially plasma exchange and lower-signal supplements — but the measurement system itself is a real advantage.
AI Recommendations
What the evidence suggests Bryan might consider
Senolytics (Quercetin + Dasatinib)
High Evidence (Animal) / Early Human
One of the strongest animal-aging signals not yet clearly established as a core Blueprint intervention.
Zhu et al., 2015 — PMID 31279025
Berberine
High Evidence (Human)
A credible metabolic alternative or complement to metformin with deep human RCT support.
Lan et al., 2015 — PMID 25861268
Taurine
High Evidence (Animal + Early Human)
One of the most important recent longevity findings, with strong animal data and low downside.
Singh et al., 2023 — PMID 37289866
Cold Exposure (Cold Water Immersion)
Moderate Evidence (Human RCTs)
A plausible, low-cost recovery and metabolic intervention that looks underrepresented in the published stack.
Esperland et al., 2022 — PMID 34393581
Acarbose
High Evidence (Animal + Epidemiological)
A serious glycemic-control candidate with unusually consistent lifespan data in animal testing.
Strong et al., 2020 — PMID 31404046
Evidence Grading
High: Multiple human RCTs or large prospective cohorts with consistent findings. Moderate: Some human trials with positive signals but limited scale or duration. Mixed: Human trials with inconsistent results. Weak: Primarily animal or mechanistic data; no compelling human endpoint evidence.
Data Sources
Primary: PubMed / MEDLINE systematic review. Secondary: Cochrane Database of Systematic Reviews, ClinicalTrials.gov trial registrations, and published ITP results.
Limitations
Human longevity trials are rare, Blueprint evolves, and evidence ratings should update as new trials publish.